Vera Therapeutics, Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
Vera Therapeutics, Inc. (VERA) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of -$47.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-27.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2024-03-27
- Vera Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-12-31 was -$2.00K.
- Vera Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-09-30 was -$15.00K.
- Vera Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-06-30 was -$29.00K.
- Vera Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-03-31 was -$1.00K.
- Vera Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was -$47.00K.
- Vera Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$809.00K.
- Vera Therapeutics, Inc. equity securities, fv-ni, unrealized gain (loss) for fiscal 2021 was -$892.00K.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 5 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 8 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$17.00K derived: sum of 2 quarters · filed 2024-03-27 | -$46.00K derived: sum of 3 quarters · filed 2024-03-27 | -$47.00K 10-K · filed 2024-03-27 | |||
| 2023-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$44.00K derived: sum of 2 quarters · filed 2023-11-09 | -$45.00K 10-Q · filed 2023-11-09 | -$109.00K derived: sum of 4 quarters · filed 2024-03-27 | |||
| 2023-06-30 | -$29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$30.00K 10-Q · filed 2023-08-10 | -$94.00K derived: sum of 3 quarters · filed 2024-03-27 | -$296.00K derived: sum of 4 quarters · filed 2024-03-27 | |||
| 2023-03-31 | -$1.00K 10-Q · filed 2023-05-11 | -$65.00K derived: sum of 2 quarters · filed 2024-03-27 | -$267.00K derived: sum of 3 quarters · filed 2024-03-27 | -$810.00K derived: sum of 4 quarters · filed 2024-03-27 | |||
| 2022-12-31 | -$64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$266.00K derived: sum of 2 quarters · filed 2024-03-27 | -$809.00K derived: sum of 3 quarters · filed 2024-03-27 | -$809.00K 10-K · filed 2024-03-27 | |||
| 2022-09-30 | -$202.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$745.00K derived: sum of 2 quarters · filed 2023-11-09 | -$745.00K 10-Q · filed 2023-11-09 | -$992.00K derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$543.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$543.00K 10-Q · filed 2023-08-10 | -$790.00K derived: sum of 3 quarters · filed 2023-08-10 | -$1.15M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | -$287.00K 10-Q · filed 2022-05-16 | -$247.00K derived: sum of 2 quarters · filed 2023-05-11 | -$611.00K derived: sum of 3 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$611.00K derived: sum of 2 quarters · filed 2023-03-28 | -$892.00K 10-K · filed 2022-03-28 | -$892.00K 10-K · filed 2023-03-28 | |||
| 2021-09-30 | -$364.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$645.00K 10-Q · filed 2021-11-10 | -$645.00K 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | -$281.00K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |